Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 271

Results For "EY"

3996 News Found

Apollo Hospitals integrates cardiovascular risk tool with ConnectedLife digital wellness solutions
Healthcare | July 06, 2022

Apollo Hospitals integrates cardiovascular risk tool with ConnectedLife digital wellness solutions

The AICVD tool can predict the risk of cardiovascular disease.


Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine
News | July 06, 2022

Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine

Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells


ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India
People | July 05, 2022

ART Fertility Clinics appoints Dr. Somesh Mittal as CEO, India

Mittal has previously managed Multiple backed Vikram Hospital as CEO and was associated with Fortis Escorts Heart Institute as zonal director.


50% of heart attacks now happens in Indians below 50 years: says Expert
Public Health | July 05, 2022

50% of heart attacks now happens in Indians below 50 years: says Expert

Younger Indians have a 10 times higher rate of heart attack


Need for national-level awareness about organ transplant surgeries & organ donation in India
Healthcare | July 05, 2022

Need for national-level awareness about organ transplant surgeries & organ donation in India

People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.


Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries
Healthcare | July 05, 2022

Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries

Medicines, including insulin, to be available in 40 lower-income countries


OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212
Drug Approval | July 04, 2022

OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212

The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.


Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing
Clinical Trials | July 04, 2022

Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing

Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection


Microsize launched as Independent pharma services company
News | July 04, 2022

Microsize launched as Independent pharma services company

Meets the growing need for US-based API solubility and bioavailability enhancement services